富瑞:予百勝中國-S(9987.HK)買入評級 目標價459.16港元
富瑞發表研究報吿指,對於百勝中國-S(9987.HK)與yum!brands關於就外送費和第三方外送平台佣金支付特許經營費爭議,相信是次事件屬小型糾紛,不會影響其與yum!brands的合作關係,予百勝中國港股目標價459.16港元,美股目標價58.5美元,均予“買入”評級。
該行表示,根據百勝中國今年首季業績報吿,在其應收賬款和應收票據中,有來自百勝中國的200萬美元許可費目前存在爭議。因此,公司昨天發佈公吿解釋相關爭議,如果是為了收回之前支付的特許權使用費,該行估計將達到3000萬至3500萬美元。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.